JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Search

CareDx Inc

Gesloten

SectorGezondheidszorg

19.35 6.09

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.24

Max

19.62

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

1.7M

Verkoop

13M

100M

K/W

Sectorgemiddelde

15.953

84.243

Winstmarge

1.674

Werknemers

644

EBITDA

11M

6.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-4.91% downside

Dividenden

By Dow Jones

Volgende Winsten

25 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

301M

1.1B

Vorige openingsprijs

13.26

Vorige sluitingsprijs

19.35

Nieuwssentiment

By Acuity

100%

0%

335 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 feb 2026, 23:57 UTC

Winsten

Naver Has Record Year Despite Weaker Final Quarter

5 feb 2026, 23:45 UTC

Populaire aandelen

Stocks to Watch: Amazon, Coty, Gen Digital, Roblox

5 feb 2026, 22:26 UTC

Winsten

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9% -- Update

5 feb 2026, 22:00 UTC

Winsten

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9%

5 feb 2026, 23:47 UTC

Marktinformatie

Global Equities Roundup: Market Talk

5 feb 2026, 23:47 UTC

Marktinformatie

Nikkei May Fall After U.S. Tech Stock Drops -- Market Talk

5 feb 2026, 23:43 UTC

Marktinformatie

Gold Falls on Spillover Impact From Cryptocurrencies' Selloff -- Market Talk

5 feb 2026, 23:37 UTC

Marktinformatie

Glencore Shares Look Cheap After Failed Takeover Talks -- Market Talk

5 feb 2026, 23:20 UTC

Winsten
Acquisities, Fusies, Overnames

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 5th Update

5 feb 2026, 23:11 UTC

Marktinformatie

Amazon CEO Confident in Return on $200B Investment -- Market Talk

5 feb 2026, 23:09 UTC

Winsten

Naver 2025 Net KRW1.820T Vs. Net KRW1.932T >035420.SE

5 feb 2026, 23:08 UTC

Winsten

Naver 2025 Oper Pft KRW2.208T Vs. Pft KRW1.979T >035420.SE

5 feb 2026, 23:07 UTC

Winsten

Naver 2025 Rev KRW12.035T Vs. KRW10.738T >035420.SE

5 feb 2026, 23:03 UTC

Marktinformatie
Winsten

REA's Update Looks Negative Despite A$200M Buyback -- Market Talk

5 feb 2026, 23:03 UTC

Winsten
Acquisities, Fusies, Overnames

Bitcoin Booster's $12 Billion Loss Headlines Crypto's Worst Day Since 2022 Crash -- WSJ

5 feb 2026, 23:00 UTC

Winsten

Naver 4Q Net Profit Missed FactSet-Compiled Consensus

5 feb 2026, 23:00 UTC

Winsten

Naver 4Q Net KRW164.60B Vs. Net KRW514.00B >035420.SE

5 feb 2026, 22:59 UTC

Winsten

Naver 4Q Oper Pft KRW610.60B Vs. Pft KRW542.00B >035420.SE

5 feb 2026, 22:59 UTC

Winsten

Naver 4Q Rev KRW3.195T Vs. KRW2.886T >035420.SE

5 feb 2026, 22:52 UTC

Winsten

Alphabet Stock Is Taking a Hit After Strong Earnings. Don't Panic. -- Barrons.com

5 feb 2026, 22:45 UTC

Winsten

Amazon Stock Falls Sharply on Earnings. Spending Continues to Soar. -- Barrons.com

5 feb 2026, 22:37 UTC

Marktinformatie

Woolworths's Profit Margin Likely Faces 2Q Squeeze -- Market Talk

5 feb 2026, 22:11 UTC

Winsten

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9% -- Update

5 feb 2026, 22:03 UTC

Winsten
Acquisities, Fusies, Overnames

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 4th Update

5 feb 2026, 22:01 UTC

Winsten

Reddit Stock Jumps on Earnings. CFO Cites Modest AI Spending. -- Barrons.com

5 feb 2026, 21:59 UTC

Marktinformatie
Acquisities, Fusies, Overnames

What's Next For Rio Tinto, Glencore After Deal Talks Fail? -- Market Talk

5 feb 2026, 21:51 UTC

Winsten
Acquisities, Fusies, Overnames

Saylor's Strategy Posts $12 Billion Quarterly Loss on Bitcoin Selloff -- WSJ

5 feb 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

5 feb 2026, 21:49 UTC

Winsten

Why Google's Bad News Was Good News for Broadcom and Nvidia -- Barrons.com

5 feb 2026, 21:45 UTC

Winsten

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9%

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

-4.91% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 18 USD  -4.91%

Hoogste 18 USD

Laagste 18 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

0

Buy

4

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

335 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat